Editorial: Factors that impact the survival of non-small cell lung cancer.
作者信息
Hegi-Johnson Fiona, Higgins Kristin A
机构信息
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC, Australia.
出版信息
Front Oncol. 2023 Feb 9;13:1148340. doi: 10.3389/fonc.2023.1148340. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Factors that impact the survival of non-small cell lung cancer.社论：影响非小细胞肺癌生存率的因素
Front Oncol. 2023 Feb 9;13:1148340. doi: 10.3389/fonc.2023.1148340. eCollection 2023.
2
[Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].[非小细胞肺癌——从免疫生物学到免疫治疗]
Klin Onkol. 2016 Fall;29 Suppl 4(Suppl 4):78-87.
3
4
Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis.新辅助放疗、辅助放疗和单纯化疗对接受手术治疗的局部晚期非小细胞肺癌患者生存的长期影响：一项倾向评分匹配分析。
BMC Cancer. 2018 Nov 6;18(1):1067. doi: 10.1186/s12885-018-4900-x.
5
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.促进抗 PD-1 治疗的疗效：纳武利尤单抗联合放疗治疗晚期非小细胞肺癌 - FORCE 试验研究方案。
BMC Cancer. 2019 Nov 8;19(1):1074. doi: 10.1186/s12885-019-6205-0.
6
Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis.放疗改善信迪利单抗免疫治疗非小细胞肺癌的疗效：一项真实世界分析。
Front Immunol. 2022 Sep 15;13:991431. doi: 10.3389/fimmu.2022.991431. eCollection 2022.
7
Adjuvant cytokine-induced killer cell immunotherapy improves long-term survival in patients with stage I-II non-small cell lung cancer after curative surgery.辅助性细胞因子诱导的杀伤细胞免疫疗法可提高I-II期非小细胞肺癌患者根治性手术后的长期生存率。
Cytotherapy. 2023 Feb;25(2):202-209. doi: 10.1016/j.jcyt.2022.10.008. Epub 2022 Nov 12.
8
The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.IIIAN2 期 NSCLC 患者放疗序贯与同步治疗的影响：一项基于人群的研究。
BMC Cancer. 2020 Aug 26;20(1):809. doi: 10.1186/s12885-020-07309-y.
9
Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.免疫检查点阻断在晚期非小细胞肺癌治疗中的应用——预测反应的因素和既往放疗的影响。
Acta Oncol. 2021 Feb;60(2):149-156. doi: 10.1080/0284186X.2020.1854851. Epub 2020 Dec 24.
10
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.PD-L1 表达在非小细胞肺癌中的意义：作为预测和预后标志物的锐利双刃剑。
Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28.
本文引用的文献
1
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.COAST 研究：度伐利尤单抗单药或联合奥雷利珠单抗或 Monalizumab 治疗不可切除 III 期非小细胞肺癌的开放标签、II 期、多药物平台研究。
J Clin Oncol. 2022 Oct 10;40(29):3383-3393. doi: 10.1200/JCO.22.00227. Epub 2022 Apr 22.
2
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
3
Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study.肺癌、上呼吸消化道癌和膀胱癌患者戒烟与生存率：队列研究
Br J Cancer. 2017 Oct 10;117(8):1224-1232. doi: 10.1038/bjc.2017.179. Epub 2017 Sep 12.
4
Imaging biomarker roadmap for cancer studies.癌症研究的影像生物标志物路线图。
Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11.
5
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
6
Avoidable global cancer deaths and total deaths from smoking.可避免的全球癌症死亡人数及吸烟导致的总死亡人数。
Nat Rev Cancer. 2009 Sep;9(9):655-64. doi: 10.1038/nrc2703. Epub 2009 Aug 20.
Zotero 插件